{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:53:09Z","timestamp":1782492789409,"version":"3.54.5"},"reference-count":28,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030841","name":"Exact Sciences Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is one of the most common cancers worldwide. Stage II\/III patients undergo curative-intent surgery yet still face the recurrence risk. Detecting recurrences early provides the best opportunity for optimal treatment. We aimed to develop a microsimulation model to evaluate CRC management-associated outcomes based on current guidelines, including the performance of guideline-recommended surveillance in detecting recurrences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Two separate individual-level state transition (microsimulation) models for colon and rectal cancer were built with a lifetime horizon using monthly cycles. The models integrated treatment and surveillance strategies per current guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The currently recommended surveillance modalities by National Comprehensive Cancer Network guidelines for surveilling patients with CRC after curative-intent surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>65-year-old patients with stage II and stage III CRC who underwent curative-intent surgery in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Cumulative recurrences, detected recurrences, detection rate, overall survival and recurrence-free survival in a 5-year horizon, as well as average life expectancy, were the outcome measures used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 5 years, disease recurrence was observed in 9.5% of patients with stage II\u2013III colon cancer and in 38.0% of patients with stage II\u2013III rectal cancer. Of these, 82.5% and 85.5% were detected via surveillance, respectively, within 5 years. The predicted 5-year overall survival was 86.0% for colon cancer and 69.3% for rectal cancer, with corresponding recurrence-free survival rates of 78.9% and 53.8%. Based on current guidelines-recommended surveillance, detecting one colon cancer recurrence requires 148 carcinoembryonic antigen (CEA) tests, 37 CT scans and 21 colonoscopies. In contrast, detecting one rectal cancer recurrence requires 31 CEA tests, 8 CT scans and 4 colonoscopies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our validated model suggests that relative to an optimal benchmark in which all recurrences are detected, recurrence detection under current guidelines may be suboptimal, indicating room for improvement. As new tests emerge, this model could be a valuable tool for evaluating existing clinical practices and the potential of new tests to enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111289","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:55:19Z","timestamp":1773406519000},"page":"e111289","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3980-8188","authenticated-orcid":false,"given":"Sumeyye","family":"Samur","sequence":"first","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Gursel","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning Yan","family":"Gu","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebra Cuyun","family":"Carter","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Sahinkoc","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"},{"name":"Institute for Technology Assessment, Harvard Medical School, Mass General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-0280","authenticated-orcid":false,"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"},{"name":"Department of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[{"name":"Value Analytics Labs, Boston, Massachusetts, USA"},{"name":"Institute for Technology Assessment, Harvard Medical School, Mass General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somasundaram","family":"Subramaniam","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Palomares","sequence":"additional","affiliation":[{"name":"Exact Sciences Corporation, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna R","family":"Parikh","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred I","family":"Neugut","sequence":"additional","affiliation":[{"name":"Medicine, Columbia University Medical Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026062609362594000_16.3.e111289.1","unstructured":"Colorectal cancer, 2024. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/colorectal-cancer"},{"key":"2026062609362594000_16.3.e111289.2","unstructured":"Key statistics for colorectal cancer, 2024. Available: https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/about\/key-statistics.html"},{"key":"2026062609362594000_16.3.e111289.3","unstructured":"Financial burden of cancer care, 2024. Available: https:\/\/progressreport.cancer.gov\/after\/economic_burden"},{"key":"2026062609362594000_16.3.e111289.4","unstructured":"Institute NC . Data from: SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2021 Sub (2000-2019). 2021."},{"key":"2026062609362594000_16.3.e111289.5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamaoncol.2023.5098","article-title":"Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study","volume":"10","author":"Nors","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026062609362594000_16.3.e111289.6","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.22"},{"key":"2026062609362594000_16.3.e111289.7","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026062609362594000_16.3.e111289.8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0051"},{"key":"2026062609362594000_16.3.e111289.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.7442"},{"key":"2026062609362594000_16.3.e111289.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"2026062609362594000_16.3.e111289.11","unstructured":"Amin M , Edge S , Greene F , et al . AJCC cancer staging manual. 8th edn. Springer International Publishing, 2017."},{"key":"2026062609362594000_16.3.e111289.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0521-7"},{"key":"2026062609362594000_16.3.e111289.13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315852"},{"key":"2026062609362594000_16.3.e111289.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02538"},{"key":"2026062609362594000_16.3.e111289.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30527-1"},{"key":"2026062609362594000_16.3.e111289.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713709"},{"key":"2026062609362594000_16.3.e111289.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.012"},{"key":"2026062609362594000_16.3.e111289.18","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2018.5816","article-title":"Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer","volume":"319","author":"Snyder","year":"2018","journal-title":"JAMA"},{"key":"2026062609362594000_16.3.e111289.19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/DCR.0000000000001558","article-title":"Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision","volume":"63","author":"Voss","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"2026062609362594000_16.3.e111289.20","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.11.40","article-title":"Prolonged follow-up of colorectal cancer patients after 5 years: to follow or not to follow, that is the question (and how)!","volume":"8","author":"Caso","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026062609362594000_16.3.e111289.21","unstructured":"Health and economic benefits of colorectal cancer interventions. 2024. Available: https:\/\/www.cdc.gov\/nccdphp\/priorities\/colorectal-cancer.html"},{"key":"2026062609362594000_16.3.e111289.22","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0490"},{"key":"2026062609362594000_16.3.e111289.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000450","article-title":"Cost-effectiveness of surveillance with CT colonography after resection of colorectal cancer","volume":"7","author":"Kuntz","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"2026062609362594000_16.3.e111289.24","first-page":"767","article-title":"Development and validation of a model to predict outcomes of colon cancer surveillance","volume":"30","author":"Rose","year":"2019","journal-title":"Cancer Causes Control"},{"key":"2026062609362594000_16.3.e111289.25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/DCR.0000000000001364","article-title":"Health and Economic Impact of Intensive Surveillance for Distant Recurrence After Curative Treatment of Colon Cancer: A Mathematical Modeling Study","volume":"62","author":"Wanis","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"2026062609362594000_16.3.e111289.26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1472-6947-14-29","article-title":"A simulation model of colorectal cancer surveillance and recurrence","volume":"14","author":"Rose","year":"2014","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026062609362594000_16.3.e111289.27","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3112"},{"key":"2026062609362594000_16.3.e111289.28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00268-004-7256-0","article-title":"Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model","volume":"28","author":"Borie","year":"2004","journal-title":"World J Surg"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:40:54Z","timestamp":1782492054000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-111289"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111289","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}